Health

The effects of non-evidence-based technologies entering the health sector

March 20, 2023

Global

The effects of non-evidence-based technologies entering the health sector

March 20, 2023

Global
Michael Guterbock

Senior Consultant, Economist Impact, Policy and insights

Michael is a Senior Consultant with Economist Impact’s Policy Team. He works with global clients developing and delivering evidence-based policy projects across a wide range of priority areas and manages Economist Impact research teams. Prior to consulting with the Economist Group, Michael worked in disaster preparedness and humanitarian assistance consulting, as well as on policy design and implementation with the US Federal Government. Michael holds a Master’s degree in International Relations from Johns Hopkins University School of Advanced International Studies (SAIS), a Master’s degree in Global Health from The University of Michigan, and is currently pursuing a Doctorate in International Affairs from Johns Hopkins SAIS.

Not all technologies entering the health sector have the clinical validation or empirical data to support claims of their medical effectiveness and successful health outcomes.

Unlike new medical devices and pharmaceutical interventions, not all healthcare technologies undergo a rigorous clinical approval process. As a result, certain technological interventions may not be grounded in scientific evidence, potentially leading to harmful effects and costly interventions without benefit for those who use them.

The future of health technologies requires accountability mechanisms to ensure quantifiable health impacts. National and international stakeholders must come together to create regulatory frameworks and set ethical industry norms. The path forward must include review and evidence standards that are equivalent to the stringent scientific standards for medical devices. These methods can help assuage the hesitancy and scepticism many in the public feel about healthcare technologies by helping to prove their benefits.

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week